Evofem, Inc. Appoints Dr. David Friend As Senior Vice President Of Product Development

SAN DIEGO, April 1, 2015 (GLOBE NEWSWIRE) -- Evofem, Inc. announces that Dr. David Friend has been named Senior Vice President of Product Development, effective immediately.

In this role, Dr. Friend will be responsible for providing scientific leadership and managing product development from initial concept to final product. He will report to Evofem's Chief Medical Officer.

"David brings an extensive scientific background coupled with global experience in women's health," said Evofem's COO, John Fair. "We look forward to his contributions to our team."

Prior to joining Evofem, Dr. Friend served as Director of Product Development at CONRAD, an organization that works to expand contraceptive choices and prevent sexually transmitted infections. Before CONRAD, Dr. Friend was Vice President, Research at Vyteris, Inc, a company that develops novel transdermal delivery systems. He has developed oral dosage forms for delivery of drugs and he holds several patents for novel dosage forms. His previous professional experience includes work at a number of pharmaceutical companies, including Delsys Pharmaceutical, a division of Elan Corporation, Vascular Therapeutics, CIBUS Pharmaceuticals and SRI International.

Dr. Friend has published more than 60 research articles and is currently on the editorial board of the Drug Delivery and Translational Research, Antiviral Research and Pharmaceutical Development and Technology Journals. Additionally, Dr. Friend sits on three scientific advisory boards in the areas of microbicide development and the prevention of HIV transmission. He earned his Bachelor of Science in biochemistry from the University of California, Davis, and his PhD in chemistry from the University of California, Berkeley.

About Evofem, Inc.

Evofem, Inc. is a privately held biotechnology company that discovers, develops and commercializes prescription and over-the-counter products in the areas of feminine care, contraception, and the prevention of sexually transmitted infections. Evofem, Inc. is committed to delivering effective, woman-controlled, rapidly reversible forms of contraception to women globally.

Media Inquiries

Ellen Thomas

+1.718.490.3248

[email protected]

CONTACT: Ellen Thomas +1.718.490.3248 [email protected]

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.